CytomX Therapeutics, Inc. short interest in 2022
In 2022, CytomX Therapeutics, Inc.'s disclosed short interest ran from 5.67% of shares outstanding on 14 Jan 2022 to 2.23% on 15 Dec 2022, a change of -3.44 percentage points. The year's high was 6.18% on 13 May 2022 and its low 1.36% on 31 Aug 2022, averaging 3.84% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.11 days on 28 Feb 2022. Full history: CytomX Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 5.67% (14 Jan 2022)
- End of year
- 2.23% (15 Dec 2022)
- Change
- -3.44 pp
- High
- 6.18% (13 May 2022)
- Low
- 1.36% (31 Aug 2022)
- Average
- 3.84%
- Highest days to cover
- 8.11 (28 Feb 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 5.67% | 4.80 | |
| 31 Jan 2022 | 5.35% | 4.03 | |
| 15 Feb 2022 | 5.97% | 5.67 | |
| 28 Feb 2022 | 5.84% | 8.11 | |
| 15 Mar 2022 | 5.85% | 5.71 | 10-K filed, results (8-K) |
| 31 Mar 2022 | 6.00% | 2.34 | |
| 14 Apr 2022 | 4.22% | 3.67 | |
| 29 Apr 2022 | 5.81% | 3.40 | |
| 13 May 2022 | 6.18% | 2.91 | 10-Q filed, results (8-K) |
| 31 May 2022 | 5.84% | 4.85 | |
| 15 Jun 2022 | 5.57% | 4.72 | |
| 29 Jul 2022 | 2.00% | 1.12 | |
| 15 Aug 2022 | 1.58% | 1.00 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 1.36% | 1.72 | |
| 15 Sep 2022 | 1.78% | 1.46 | |
| 30 Sep 2022 | 1.81% | 3.09 | |
| 14 Oct 2022 | 1.62% | 2.51 | |
| 31 Oct 2022 | 1.51% | 3.64 | |
| 15 Nov 2022 | 1.48% | 3.25 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 3.01% | 1.00 | |
| 15 Dec 2022 | 2.23% | 1.78 |
See also: CytomX Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.